Citations

Clear

114 citation(s) found for "Maria, Lapid".

Analyses of Quality of Life in Frontotemporal Lobar Degeneration: Findings from the ALLFTD Consortium
Nelson, Kevin M., Forsberg, Leah K. , Brushaber, Danielle , Syrjanen, Jeremy A. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lapid, Maria I. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S19 | Pages: No page available

10.1002/alz.080591 Get It

AbstractBackgroundThe DEMQOL (Dementia Quality of Life) scale is a patient reported questionnaire and proxy form that captures subjective life quality. Participants in ALLFTD and their Study Partners (SP) complete these questionnaires at each study visit.MethodWe analyzed the DEMQOL in participants and their SPs when the SP was reported to be a spouse or equivalent. Analyses focused on the final overall quality of life (QoL) rating for the participant (poor, fair, good, or very good).ResultDEMQOL responses from 907 dyads (participant: mean age 58.3±13.4 years, 44% female, and mean education 15.9±2.5 years) were analyzed. Participants rated their overall QoL as very good (45.8%), good (36.5%), fair (14%), and poor (3.5%). SPs rated their participant’s overall QoL as very good (33.6%), good (41%), fair (19.4%), and poor (6%). There was a discordance in ratings between participants and SPs (p<0.0001); in almost 50% of cases, participants rated their QoL better (33.2%) or worse (15.2%) than their SP rated their QoL. When considering disease severity (CDR®+NACC‐FTLD global score), participants rated their QoL better than their SP rated their QoL (CDR®+NACC‐FTLD = 0: 19.4%, CDR®+NACC‐FTLD = 0.5: 42%, and CDR®+NACC‐FTLD = 1+: 33.2%), worse than (CDR®+NACC‐FTLD = 0: 15.1%, CDR®+NACC‐FTLD = 0.5: 13.3%, and CDR®+NACC‐FTLD = 1+: 15.2%), or the same (CDR®+NACC‐FTLD = 0: 65.6%, CDR®+NACC‐FTLD = 0.5: 44.8%, and CDR®+NACC‐FTLD = 1+: 51.6%).ConclusionAmong participants and SPs, similarities and differences in QoL ratings are fairly consistent regardless of global CDR®+NACC‐FTLD rating. Generally, participants are equally or more optimistic about QoL than their SPs. Longitudinal analyses are forthcoming.
Assessing patterns of network degeneration in familial frontotemporal lobar degeneration using FDG‐PET and unsupervised machine learning
Barnard, Leland R , Przybelski, Scott A. , Gogineni, Venkatsampath, Radford, Jonathan Graff, Forsberg, Leah K. , Fields, Julie A. , Rademakers, Rosa , Gavrilova, Ralitza H. , Knopman, David S. , Lowe, Val J. , Petersen, Ronald C. , Corriveau‐Lecavalier, Nick , Botha, Hugo , Ramanan, Vijay K. , Lapid, Maria I. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S16 | Pages: No page available

10.1002/alz.076725 Get It

AbstractBackgroundGenetic mutations causative of familial fronto‐temporal lobar degeneration (f‐FTLD) are highly predictive of a specific proteinopathy, but there exists substantial inter‐individual variability in their system‐level pathophysiology, which can be assessed with 18Fluorodeoxyglucose‐positron emission tomography (FDG‐PET). Determining data‐driven patterns of network degeneration suggestive of underlying specific FTLD‐related genetic mutations is paramount to guide complex clinical decision making supported by the quantification of FDG‐PET.MethodWe collected clinical and FDG‐PET data from 39 patients with f‐FTLD, including 11 carrying the C9orf72 hexanucleotide expansion (1 asymptomatic, 9 with a predominant behavioral phenotype, 1 with a predominant language phenotype), 12 carrying a GRN mutation (1 asymptomatic, 7 behavioral, 4 language), and 16 carrying a MAPT mutation (6 asymptomatic, 10 behavioral). We performed a spectral covariance decomposition analysis between FDG‐PET images to yield latent patterns reflective of a distribution of metabolism opposing poles of relative hyper‐ and hypo‐metabolism across the entire brain (“eigenbrains” or EBs). We then conducted linear discriminant analyses (LDAs) to perform EB‐based multiclass predictions of genetic mutation and clinical phenotype.ResultThe spectral decomposition analysis yielded five eigenbrains, which explained 58.79% of the covariance between FDG‐PET images (Fig. 1). Gradients indicative of relative hypometabolism in left fronto‐temporo‐parietal areas distinguished GRN mutation carriers from other genetic mutations (EB1, EB2, EB4) and were associated with clinical phenotypes predominantly involving language (EB1, EB2, EB3). Conversely, those indicative of relative hypometabolism in prefrontal areas (EB3) and temporopolar areas (EB2) with a right hemispheric predominance were mostly associated with clinical phenotypes predominantly involving behavior/personality, and EB2 distinguished MAPT mutation carriers from other genetic mutations. The LDAs yielded accuracies of 80% and 75% in predicting genetic status and predominant clinical phenotype, respectively (Fig. 2).ConclusionFive EBs explained a high proportion of covariance in patterns of network degeneration across FTLD‐related genetic mutations. These EBs contained information relevant to the system‐level physiology associated with FTLD‐related pathogenic mechanisms and that allowed the prediction of clinical phenotype with relatively high accuracy. This supports the utility of FDG‐PET to guide the development of tools supporting clinical decision making and ongoing efforts to develop network‐based biomarkers to track disease progression and risk of phenoconversion in f‐FTLD.
ELECTROCONVULSIVE THERAPY FOR TREATMENT OF TACTILE HALLUCINATIONS
Kummerlowe, Megan N. , Utter, Kierstin , Maria, Lapid, Maria, Lapid

Mayo Clinic

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 754-754

10.1093/geroni/igad104.2438 Get It

Abstract Tactile hallucinations can be highly distressing and lead to psychiatric morbidities and functional impairments. There are no established treatments for tactile hallucinations that occur outside of primary psychotic disorders, and available pharmacologic and nonpharmacologic therapies may have limited effectiveness. We present a case of a 75-year-old female with treatment-refractory tactile hallucinations successfully treated with electroconvulsive therapy (ECT). She endorsed 13 months of distressing tactile hallucinations described as slimly substances on her skin. Symptoms started insidiously, became more severe with time and refractory to multiple antipsychotic medications. She became so severely distressed from the tactile hallucinations that she developed a major depressive episode and became suicidal. Relevant medical history included one prior depressive episode, occipital lobe stroke, restless legs syndrome, and obstructive sleep apnea. She was hospitalized in an inpatient psychogeriatric unit and treated with ECT for 12 sessions over 3.5 weeks. Hallucinations responded well to ECT. Patient experienced some mild memory impairment from treatment. Treatment was optimized with duloxetine titration, addition of mirtazapine and repletion of B6 vitamin. Following the acute course of ECT, she reported an 80 % improvement in tactile hallucinations. Depressive symptoms improved, and suicidal thoughts resolved. She was able to discharge from the hospital and continued with maintenance ECT. Our case illustrates the potential therapeutic role of brain stimulation in the treatment of refractory cases of tactile hallucinations. Further studies are needed to determine effective treatment strategies for treatment-refractory tactile hallucinations to prevent progression to severe psychiatric disturbances and improve quality of life.
EXPLORING THE COMPLEXITY OF LUCID EPISODES IN DEMENTIA: PERSPECTIVES FROM MULTIDISCIPLINARY CLINICAL EXPERTS
Bangerter, Lauren R. , Maria, Lapid, Finnie, Dawne, Frangiosa, Theresa, Griffin, Joan M. , Kim, Kyungmin , Gaugler, Joseph E.

Mayo Clinic

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 1037-1037

10.1093/geroni/igad104.3333 Get It

Abstract Lucid episodes (LE) occur in people living with dementia who have seemingly lost cognitive capacity. Understanding LEs is a relatively new area of scientific inquiry. Most LE studies have utilized different conceptual and operational definitions. Reaching a definition of LE is critical foundation to facilitate more systematic investigation and new knowledge of LEs. The goal of this study was to convene a group of 13 clinical experts to brainstorm on the key components needed to understand LE among people living with dementia (PLWD). We aimed to reach consensus from the group on (1) potential medical or clinical explanations for LEs; (2) necessary medical and clinical questions to understand LE; (3) interpretation of the presence of LE. Thirteen experts from different disciplines (neurology, psychiatry, psychology, pharmacy, palliative care, hospice, nursing, social work, primary care, geriatrics, and professional home caregivers) participated in a virtual Delphi Method study. Experts provided a range of opinions on potential medical and clinical explanations for LE, necessary questions to understand LE, and did not reach consensus on the presence of LE when presented with clinical vignettes. Panelists highlighted key medical and contextual factors as well as a need to know more information about the general demeanor and typical behavior of the PLWD to make a definitive judgement about whether LE occurred. Clinical consensus on LEs is complex. There is great variability in how behaviors and cognitive fluctuations in PLWD are appraised by clinical experts.
A MIXED METHODS APPROACH TO UNDERSTANDING SPOUSE AND CHILD CAREGIVERS’ EXPERIENCES OF LUCID EPISODES IN DEMENTIA
Bangerter, Lauren R. , Finnie, Dawne, Maria, Lapid, Frangiosa, Theresa, Kim, Kyungmin , Gaugler, Joseph E. , Maria, Lapid, Griffin, Joan M.

Mayo Clinic

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 978-978

10.1093/geroni/igad104.3143 Get It

Abstract Lucid episodes (LE) in people living with late-stages of dementia (PLWD) have been reported anecdotally, but less is known about how this seemingly unexpected phenomenon is experienced by family members. This study aims to examine variability in family caregivers’ experiences with LE, focusing on the two most common groups of informal caregivers, spouses and children—whether they may exhibit differential appraisals of and responses to LEs. Using a sample of former and current family caregivers from UsAgainstAlzheimer’s A-LIST, we conducted an online survey to spouse and child caregivers (N = 387). Qualitative semi-structured interviews were also conducted with a subset of these caregivers who have witnessed an LE (n = 22). Survey results indicate that child caregivers were more likely to witness a LE. Among “former” caregivers who have witnessed a LE (n = 140), spouses were likely to appraise LEs more negatively and make changes in care decisions (i.e., end-of-life planning and financial decisions) after LE, compared to child caregivers. Among “current” caregivers who have witnessed a LE (n = 80), spouses were more likely to indicate no special circumstances prior to LE, whereas children were more likely to indicate LEs associated with visits from friends and family; there was no difference in positive and negative appraisals of LE between current spouse and child caregivers. Content analysis of qualitative interviews revealed that observed differences between spouses and children were related to their different caregiving contexts, such as relationship history, living arrangement, expectations/motivation, and care resources.
Characteristics and Progress on 312 Subjects in the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol (P3.036)
Boeve, Bradley, Rosen, Howard, Boxer, Adam, Brushaber, Danielle, Coppola, Giovanni, Dheel, Christina, Dickerson, Bradford, Faber, Kelley, Fields, Julie, Fong, Jamie, Foroud, Tatiana, Gavrilova, Ralitza, Ghoshal, Nupur, Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grossman, Murray, Heuer, Hilary, Hsiao, John, Hsiung, Ging-Yuek, Huey, Edward, Irwin, David, Jones, David, Kantarci, Kejal, Karydas, Anna, Knopman, David, Kornak, John, Kramer, Joel, Kukull, Walter, Lapid, Maria, Mackenzie, Ian R.A., Miller, Bruce, Petrucelli, Leonard, Potter, Madeline, Rademakers, Rosa, Rankin, Katherine, Sutherland, Margaret, Syrjanen, Jeremy, Taylor, Joanne, Toga, Arthur, Weintraub, Sandra, Wszolek, Zbigniew, Boeve, Bradley, Rosen, Howard, Boxer, Adam, Brushaber, Danielle, Coppola, Giovanni, Dheel, Christina, Dickerson, Bradford, Faber, Kelley, Fields, Julie, Fong, Jamie, Foroud, Tatiana, Gavrilova, Ralitza, Ghoshal, Nupur, Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grossman, Murray, Heuer, Hilary, Hsiao, John, Hsiung, Ging-Yuek, Huey, Edward, Irwin, David, Jones, David, Kantarci, Kejal, Karydas, Anna, Knopman, David, Kornak, John, Kramer, Joel, Kukull, Walter, Lapid, Maria, Mackenzie, Ian R.A., Miller, Bruce, Petrucelli, Leonard, Potter, Madeline, Rademakers, Rosa, Rankin, Katherine, Sutherland, Margaret, Syrjanen, Jeremy, Taylor, Joanne, Toga, Arthur, Weintraub, Sandra, Wszolek, Zbigniew

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p3.036 Get It

Prominent Auditory Hallucinations in Behavioral Variant Frontotemporal Dementia Associated with a MAPT Mutation (P3.1-006)
Widmeyer, Mary, Gavrilova, Ralitza, Fields, Julie A. , Forsberg, Leah K. , Lowe, Val J. , Lapid, Maria I. , Kantarci, Kejal , Boeve, Bradley F.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p3.1-006 Get It

Impact of Armodafinil Therapy on Neuropsychiatric Features in Dementia with Lewy Bodies (S1.004)
Kuntz, Karen M. , Mason, Sara S., Aakre, Jeremiah A. , Boeve, Bradley, Lapid, Maria I. , Lundt, Emily S.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s1.004 Get It

Impact of Armodafinil Therapy on Neuropsychiatric Features in Dementia with Lewy Bodies (I9.003)
Kuntz, Karen M. , Mason, Sara S., Aakre, Jeremiah A. , Lapid, Maria I. , Lundt, Emily S. , Boeve, Bradley F.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.i9.003 Get It